# Oramed Pharmaceuticals Inc.: financial statements, quarterly

ORMP · Nasdaq · CIK 1176309 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/ormp.md) · [Financials](/companies/ormp/financials.md) · [Filings](/companies/ormp/filings.md) · [Insiders](/companies/ormp/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/ormp/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0 d](/filings/0001213900-24-095397.md) | [0.0 d](/filings/0001013762-25-003450.md) | not reported | not reported | not reported | not reported | [2.0](/filings/0001213900-26-059112.md) | [0.0 d](/filings/0001213900-26-087361.md) | [0.0 d](/filings/0001213900-25-109980.md) | [0.0 d](/filings/0001213900-26-034835.md) | not reported | not reported |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | [2.0](/filings/0001213900-26-059112.md) | [0.0 d](/filings/0001213900-26-087361.md) | [0.0 d](/filings/0001213900-25-109980.md) | [0.0 d](/filings/0001213900-26-034835.md) | not reported | not reported |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001213900-26-059112.md) | [0.0 d](/filings/0001213900-26-087361.md) | [0.0 d](/filings/0001213900-25-109980.md) | [0.0 d](/filings/0001213900-26-034835.md) | not reported | not reported |
| Research and development | $m | [1.0](/filings/0001213900-24-095397.md) | [1.8 d](/filings/0001013762-25-003450.md) | [1.2](/filings/0001213900-25-044193.md) | [1.4](/filings/0001213900-25-076668.md) | [2.2](/filings/0001213900-25-109980.md) | [1.5 d](/filings/0001213900-26-034835.md) | [2.2](/filings/0001213900-26-059112.md) | [1.0](/filings/0001213900-26-087361.md) | [1.2](/filings/0001213900-25-109980.md) | [2.0 d](/filings/0001213900-26-034835.md) | [1.6](/filings/0001213900-26-059112.md) | [0.0 d](/filings/0001213900-26-087361.md) |
| Operating income | $m | [(2.9)](/filings/0001213900-24-095397.md) | [(3.9) d](/filings/0001013762-25-003450.md) | [(3.0)](/filings/0001213900-25-044193.md) | [(3.1)](/filings/0001213900-25-076668.md) | [(3.1)](/filings/0001213900-25-109980.md) | [(3.6) d](/filings/0001213900-26-034835.md) | [(4.5)](/filings/0001213900-26-059112.md) | [(2.5)](/filings/0001213900-26-087361.md) | [(2.4)](/filings/0001213900-25-109980.md) | [(5.7) d](/filings/0001213900-26-034835.md) | [(3.7)](/filings/0001213900-26-059112.md) | [(2.8)](/filings/0001213900-26-087361.md) |
| Interest expense | $m | [0.8](/filings/0001213900-23-085310.md) | [1.2 d](/filings/0001213900-24-020485.md) | [0.6](/filings/0001213900-24-041364.md) | [0.3](/filings/0001213900-25-076668.md) | [0.0 d](/filings/0001213900-25-109980.md) | [0.0 d](/filings/0001213900-26-034835.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | not reported | not reported | not reported | [1.6](/filings/0001213900-25-076668.md) | [1.1](/filings/0001213900-25-109980.md) | [0.4 d](/filings/0001213900-26-034835.md) | [0.6](/filings/0001213900-26-059112.md) | [(0.1)](/filings/0001213900-26-087361.md) | [11.1](/filings/0001213900-25-109980.md) | [(0.2) d](/filings/0001213900-26-034835.md) | [11.1](/filings/0001213900-26-059112.md) | [23.4](/filings/0001213900-26-087361.md) |
| Net income | $m | [(3.2)](/filings/0001213900-24-095397.md) | [12.9 d](/filings/0001013762-25-003450.md) | [1.5](/filings/0001213900-25-044193.md) | [9.2](/filings/0001213900-25-076668.md) | [(19.6)](/filings/0001213900-25-109980.md) | [(10.2) d](/filings/0001213900-26-034835.md) | [(7.6)](/filings/0001213900-26-059112.md) | [13.3](/filings/0001213900-26-087361.md) | [48.4](/filings/0001213900-25-109980.md) | [10.0 d](/filings/0001213900-26-034835.md) | [38.3](/filings/0001213900-26-059112.md) | [78.2](/filings/0001213900-26-087361.md) |
| Diluted EPS | $ per share | [(0.08)](/filings/0001213900-24-095397.md) | not reported | [0.04](/filings/0001213900-25-044193.md) | [0.22](/filings/0001213900-25-076668.md) | [(0.48)](/filings/0001213900-25-109980.md) | not reported | [(0.19)](/filings/0001213900-26-059112.md) | [0.31](/filings/0001213900-26-087361.md) | [1.13](/filings/0001213900-25-109980.md) | not reported | [0.91](/filings/0001213900-26-059112.md) | [1.84](/filings/0001213900-26-087361.md) |
| Basic EPS | $ per share | [(0.08)](/filings/0001213900-24-095397.md) | not reported | [0.04](/filings/0001213900-25-044193.md) | [0.22](/filings/0001213900-25-076668.md) | [(0.48)](/filings/0001213900-25-109980.md) | not reported | [(0.19)](/filings/0001213900-26-059112.md) | [0.32](/filings/0001213900-26-087361.md) | [1.16](/filings/0001213900-25-109980.md) | not reported | [0.94](/filings/0001213900-26-059112.md) | [1.90](/filings/0001213900-26-087361.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense, us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | [9.1](/filings/0001213900-24-041364.md) | [18.6](/filings/0001213900-24-041364.md) | [10.0](/filings/0001213900-24-068992.md) | not reported | [54.4](/filings/0001213900-26-034835.md) | not reported | [15.8](/filings/0001213900-25-076668.md) | [52.2](/filings/0001213900-25-109980.md) | [45.9](/filings/0001213900-26-087361.md) | [13.2](/filings/0001213900-26-059112.md) | [15.2](/filings/0001213900-26-087361.md) |
| Current assets | $m | [176](/filings/0001213900-23-085310.md) | [163](/filings/0001013762-25-003450.md) | [177](/filings/0001213900-24-041364.md) | [153](/filings/0001213900-24-068992.md) | [143](/filings/0001213900-24-095397.md) | [143](/filings/0001213900-26-034835.md) | [131](/filings/0001213900-25-044193.md) | [99.0](/filings/0001213900-25-076668.md) | [136](/filings/0001213900-25-109980.md) | [133](/filings/0001213900-26-087361.md) | [68.2](/filings/0001213900-26-059112.md) | [53.4](/filings/0001213900-26-087361.md) |
| Total assets | $m | [231](/filings/0001213900-23-085310.md) | [221](/filings/0001013762-25-003450.md) | [204](/filings/0001213900-24-041364.md) | [184](/filings/0001213900-24-068992.md) | [165](/filings/0001213900-24-095397.md) | [155](/filings/0001213900-26-034835.md) | [148](/filings/0001213900-25-044193.md) | [162](/filings/0001213900-25-076668.md) | [220](/filings/0001213900-25-109980.md) | [231](/filings/0001213900-26-087361.md) | [269](/filings/0001213900-26-059112.md) | [370](/filings/0001213900-26-087361.md) |
| Current liabilities | $m | [78.2](/filings/0001213900-23-085310.md) | [53.2](/filings/0001013762-25-003450.md) | [33.6](/filings/0001213900-24-041364.md) | [3.7](/filings/0001213900-24-068992.md) | [5.3](/filings/0001213900-24-095397.md) | [5.7](/filings/0001213900-26-034835.md) | [5.5](/filings/0001213900-25-044193.md) | [3.7](/filings/0001213900-25-076668.md) | [6.1](/filings/0001213900-25-109980.md) | [19.1](/filings/0001213900-26-087361.md) | [10.6](/filings/0001213900-26-059112.md) | [10.7](/filings/0001213900-26-087361.md) |
| Total liabilities | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Long-term debt | $m | [74.6](/filings/0001213900-23-085310.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Short-term borrowings | $m | [75.4](/filings/0001213900-23-085310.md) | [51.0](/filings/0001013762-25-003450.md) | [32.0](/filings/0001213900-24-041364.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [149](/filings/0001213900-23-085310.md) | [164](/filings/0001013762-25-003450.md) | [167](/filings/0001213900-24-041364.md) | [177](/filings/0001213900-24-068992.md) | [156](/filings/0001213900-24-095397.md) | [146](/filings/0001213900-26-034835.md) | [141](/filings/0001213900-25-044193.md) | [155](/filings/0001213900-25-076668.md) | [203](/filings/0001213900-25-109980.md) | [200](/filings/0001213900-26-034835.md) | [238](/filings/0001213900-26-087361.md) | [317](/filings/0001213900-26-087361.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: not reported
- Long-term debt: us-gaap:LongTermDebt
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity, us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(0.7) d](/filings/0001213900-24-095397.md) | [(1.4) d](/filings/0001013762-25-003450.md) | [(1.5)](/filings/0001213900-25-044193.md) | [2.1 d](/filings/0001213900-25-076668.md) | [(7.1) d](/filings/0001213900-25-109980.md) | [(1.9) d](/filings/0001213900-26-034835.md) | [(3.5)](/filings/0001213900-26-059112.md) | [(3.5) d](/filings/0001213900-26-087361.md) | [(1.6) d](/filings/0001213900-25-109980.md) | [(0.5) d](/filings/0001213900-26-034835.md) | [(2.9)](/filings/0001213900-26-059112.md) | [(0.2) d](/filings/0001213900-26-087361.md) |
| Capital expenditure | $m | [0.0 d](/filings/0001213900-24-095397.md) | [0.0 d](/filings/0001013762-25-003450.md) | [0.0](/filings/0001213900-25-044193.md) | [0.0 d](/filings/0001213900-25-076668.md) | [0.0 d](/filings/0001213900-25-109980.md) | [0.0 d](/filings/0001213900-26-034835.md) | [0.0](/filings/0001213900-26-059112.md) | [0.0 d](/filings/0001213900-26-087361.md) | [0.0 d](/filings/0001213900-25-109980.md) | [0.0 d](/filings/0001213900-26-034835.md) | [0.0](/filings/0001213900-26-059112.md) | [0.0 d](/filings/0001213900-26-087361.md) |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | [10.4](/filings/0001213900-26-059112.md) | [0.1 d](/filings/0001213900-26-087361.md) |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | [1.2 d](/filings/0001213900-26-034835.md) | not reported | not reported | [0.4 d](/filings/0001213900-25-109980.md) | [4.0 d](/filings/0001213900-26-034835.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [39.1](/filings/0001213900-23-085310.md) | [40.0](/filings/0001213900-24-041364.md) | [40.2](/filings/0001213900-24-068992.md) | [40.4](/filings/0001213900-24-095397.md) | [41.6](/filings/0001213900-25-044193.md) | [41.6](/filings/0001213900-25-076668.md) | [40.9](/filings/0001213900-25-109980.md) | [41.2](/filings/0001213900-26-059112.md) | [42.6](/filings/0001213900-26-087361.md) | [42.8](/filings/0001213900-25-109980.md) | [42.0](/filings/0001213900-26-059112.md) | [42.5](/filings/0001213900-26-087361.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 41,597,354 at 2026-08-10, from the cover of the [10-Q filed 2026-08-10](/filings/0001213900-26-087361.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.